Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Outlook Therapeutics (OTLK) stock

Learn how to easily invest in Outlook Therapeutics stock.

Outlook Therapeutics, Inc
NASDAQ: OTLK - USD
BIOTECHNOLOGY
$0
-

Outlook Therapeutics, Inc is a biotechnology business based in the US. Outlook Therapeutics shares (OTLK) are listed on the NASDAQ and all prices are listed in US Dollars. Outlook Therapeutics employs 8 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Outlook Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OTLK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Outlook Therapeutics stock price (NASDAQ: OTLK)

Use our graph to track the performance of OTLK stocks over time.

Outlook Therapeutics shares at a glance

Information last updated 2021-07-23.
Latest market close$2.68
52-week range$0.58 - $4.26
50-day moving average $2.49
200-day moving average $2.15
Wall St. target price$5.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.89

Buy Outlook Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Outlook Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Outlook Therapeutics price performance over time

Historical closes compared with the close of $2.68 from 2021-05-28

1 week (2021-07-15) N/A
1 month (2021-06-25) 10.74%
3 months (2021-04-26) 18.06%
6 months (2021-01-22) N/A
1 year (2020-07-22) N/A
2 years (2019-07-22) N/A
3 years (2018-07-22) N/A
5 years (2016-07-22) N/A

Outlook Therapeutics financials

Revenue TTM $5.9 million
Gross profit TTM $-26,341,998
Return on assets TTM -104.25%
Return on equity TTM -64034.97%
Profit margin 0%
Book value $0.12
Market capitalisation $430.5 million

TTM: trailing 12 months

Shorting Outlook Therapeutics shares

There are currently 4.2 million Outlook Therapeutics shares held short by investors – that's known as Outlook Therapeutics's "short interest". This figure is 214.1% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Outlook Therapeutics shares can be evaluated.

Outlook Therapeutics's "short interest ratio" (SIR)

Outlook Therapeutics's "short interest ratio" (SIR) is the quantity of Outlook Therapeutics shares currently shorted divided by the average quantity of Outlook Therapeutics shares traded daily (recently around 1.3 million). Outlook Therapeutics's SIR currently stands at 3.37. In other words for every 100,000 Outlook Therapeutics shares traded daily on the market, roughly 3370 shares are currently held short.

However Outlook Therapeutics's short interest can also be evaluated against the total number of Outlook Therapeutics shares, or, against the total number of tradable Outlook Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Outlook Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Outlook Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0475% of the tradable shares (for every 100,000 tradable Outlook Therapeutics shares, roughly 48 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Outlook Therapeutics.

Find out more about how you can short Outlook Therapeutics stock.

Outlook Therapeutics share dividends

We're not expecting Outlook Therapeutics to pay a dividend over the next 12 months.

Have Outlook Therapeutics's shares ever split?

Outlook Therapeutics's shares were split on a 1:8 basis on 17 March 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Outlook Therapeutics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Outlook Therapeutics shares which in turn could have impacted Outlook Therapeutics's share price.

Outlook Therapeutics share price volatility

Over the last 12 months, Outlook Therapeutics's shares have ranged in value from as little as $0.58 up to $4.26. A popular way to gauge a stock's volatility is its "beta".

OTLK.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Outlook Therapeutics's is 0.6817. This would suggest that Outlook Therapeutics's shares are less volatile than average (for this exchange).

Outlook Therapeutics overview

Outlook Therapeutics, Inc. , a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S. A. de C.

Stocks similar to Outlook Therapeutics

Frequently asked questions

What percentage of Outlook Therapeutics is owned by insiders or institutions?
Currently 48.37% of Outlook Therapeutics shares are held by insiders and 9.024% by institutions.
How many people work for Outlook Therapeutics?
Latest data suggests 8 work at Outlook Therapeutics.
When does the fiscal year end for Outlook Therapeutics?
Outlook Therapeutics's fiscal year ends in September.
Where is Outlook Therapeutics based?
Outlook Therapeutics's address is: 4260 U.S. Route 1, Cranbury, NJ, United States, 08852
What is Outlook Therapeutics's ISIN number?
Outlook Therapeutics's international securities identification number is: US69012T2069
What is Outlook Therapeutics's CUSIP number?
Outlook Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68235M105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site